The Pennant Group, Inc. (PNTG) fair value analysis
Nasdaq · Updated 2026-10-19
PNTG price how computed
Forward Fair Value verdict
Fairly valuedPNTG is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $41.87
- Sector
- Healthcare
- 12-month range
- $23.75–$42.48
- Market cap
- $1.46B
- From 52-week high
- -1.4%
- Shares outstanding
- 34.9M
- Rank in Healthcare by discount to fair value
- #71 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
The Pennant Group, Inc. is a healthcare services company that operates skilled nursing facilities, assisted living facilities, and other senior care communities. The company operates facilities across multiple states in the United States.
PNTG currently ranks #71 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.46B
- P/E (trailing)
- 35x
- Revenue (TTM)
- $1.1B
- Net margin
- 2.9%
- EPS (TTM)
- $1.20
- Gross margin
- 14.1%
- Debt / equity
- 1.38
- Revenue growth (3-yr avg)
- 37.5%
- Shares outstanding
- 34.9M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 59 · neutral
- 50-day average
- $39.40
- 200-day average
- $34.78
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 6 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+3.6%)
2026-03 ▲ beat (+3.2%)
2025-12 ▲ beat (+7.7%)
2025-09 ▲ beat (+4.2%)
2025-06 ▬ met (0.0%)
2025-03 ▲ beat (+12.5%)
2024-12 ▬ met (0.0%)
2024-09 ▲ beat (+13.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 0 hold · 0 sell (7 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $46.8
- Target vs last price
- +11.8%
What our data shows for PNTG
- Our model validated 17 trailing price-to-earnings windows for PNTG, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $23.75–$42.48.
- The 14-day relative strength index sits at a neutral 59.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PNTG
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent PNTG news
TickrTrends' derived news-sentiment signal for PNTG is currently leaning positive, computed from recent coverage.
- Pennant Group Inc (PNTG) Stock Down 3.7% but Still Overvalued -- GF Score: 92/100 (gurufocus.com, 2026-10-01)
TickrTrends take: PNTG's recent decline stands in contrast to TickrTrends' assessment that the stock is fairly valued, suggesting the market may be recalibrating its view of the company. The high GF Score indicates strong fundamental quality in the Healthcare sector company, which could support the stock if investor sentiment shifts back toward valuation fundamentals. For investors focused on valuation, the gap between the negative price momentum and the positive quality metrics presents a point to monitor regarding whether the stock's fair value status will hold or shift as conditions evolve. - Are You Looking for a Top Momentum Pick? Why The Pennant Group, Inc. (PNTG) is a Great Choice (zacks.com, 2026-09-21)
TickrTrends take: The Pennant Group operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends analysis. A momentum-focused investment thesis would need to be weighed against this fair valuation baseline, as momentum strategies and valuation metrics can point toward different conclusions about near-term performance. Healthcare investors monitoring PNTG should consider whether recent momentum signals justify entry at current pricing or whether the fairly valued status suggests limited upside from valuation expansion. - The Pennant Group: The Pros Of Investing Continue To Outweigh The Cons (NASDAQ:PNTG) (seekingalpha.com, 2026-09-18)
TickrTrends take: The Pennant Group operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends metrics. Given that the company is neither undervalued nor overvalued at current prices, investors focused on valuation should monitor whether operational performance improvements or margin expansion might justify a shift in this assessment. Any changes to the company's fundamental metrics or sector dynamics could alter the fairly valued positioning in either direction.
What people are saying
Follow the PNTG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — PNTG's sector discount rank declined to number 85 this week from number 78, indicating a relative weakening in its valuation position within the Healthcare sector. The stock maintains a Fairly valued assessment according to TickrTrends' derived indicators.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — PNTG's 50/200-day trend state shifted from mixed to uptrend this week, while its sector discount rank moved from #74 to #79 within the Healthcare sector. The stock maintains a fairly valued assessment according to current valuations.
- 2026-10-05 — PNTG has experienced notable shifts in its technical indicators over the past week. The 50/200-day trend state has transitioned from an uptrend to a mixed state, suggesting reduced directional momentum, while the stock's sector discount rank improved to #74 from #83, indicating a relatively stronger valuation position within the Healthcare sector. At its current valuation of fairly valued, PNTG reflects these technical adjustments.
- 2026-09-28 — PNTG's technical positioning improved this week as the 50/200-day trend state transitioned from mixed to uptrend, suggesting strengthening momentum in the near term. The stock's sector discount rank moved from 72 to 83, indicating it has become relatively more expensive compared to other Healthcare sector companies. The current valuation verdict remains Fairly valued.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is PNTG stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), PNTG is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is PNTG's TickrTrends verdict?
PNTG's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does PNTG compare to other Healthcare stocks?
PNTG ranks #71 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is PNTG overbought or oversold?
PNTG's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does PNTG report earnings next?
PNTG's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does PNTG usually beat earnings estimates?
Over its last 8 reported quarters PNTG beat the consensus estimate 6 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about PNTG?
Of 7 analysts covering PNTG, 7 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $46.8 (+11.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
PNTG vs ACAD · PNTG vs BIIB · PNTG vs BMY · PNTG vs BVS · PNTG vs CAH